Skip to main content

-

Technology Guidance - Drug

Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia First Published on 2 July 2018


Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Alfuzosin 10 mg tablet and dutasteride 0.5 mg capsule for treating benign prostatic hyperplasia

Subsidy status

Alfuzosin 10 mg tablet and dutasteride 0.5 mg capsule are recommended for inclusion on the MOH Standard Drug List (SDL).

SDL subsidy does not apply to tamsulosin 0.4 mg tablet or dutasteride 0.5 mg/tamsulosin 0.4 mg capsule.


Get Acrobat Readeropens in a new window
Back to Top